Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

HIV vaccines in a prior HIV vaccine trial

Immunosuppressive medications within 168 days prior to first vaccination

Blood products within 120 days prior to first vaccination

Immunoglobulin within 60 days prior to first vaccination

Live attenuated vaccines within 30 days prior to first vaccination

Investigational research agents within 30 days prior to first vaccination

Medically indicated subunit or killed vaccines within 14 days prior to first study vaccine administration, or allergy treatment with antigen injections within 30 days prior to first vaccination

Current tuberculosis prophylaxis or therapy

Clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect current health

Any medical, psychiatric, or social condition that would interfere with the study. More information about this criterion can be found in the protocol.

Any job-related responsibility that would interfere with the study

Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded.

Autoimmune disease or immunodeficiency

Active syphilis infection unless the participant has completed full treatment for syphilis 6 months prior to enrollment

Unstable asthma

Diabetes mellitus type 1 or 2

Thyroid disease or thyroidectomy requiring treatment

Serious angioedema within 3 years prior to enrollment

Uncontrolled hypertension

Body mass index (BMI) of 40 or greater

BMI of 35 or greater if the participant is older than 45 years, has systolic blood pressure greater than 140 mm Hg, has diastolic blood pressure greater than 90 mm Hg, smokes, or has known hyperlipidemia

Bleeding disorder

Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period

Seizure disorder requiring medication within the 3 years prior to enrollment

Absence of the spleen

Mental illness that would interfere with the study

Other conditions that, in the judgment of the investigator, would interfere with the study

Pregnancy, breastfeeding, or plans to become pregnant

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

What this study is about

Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults

What this study is about